About

Neurodegeneration Therapeutics, Inc (NTI) is 501(c)3 not-for-profit biomedical research company that exists both to discover knowledge about the heterogeneity of adult brain diseases (Alzheimer’s (AD), Parkinson’s (PD), Lou Gherig’s (aka ALS)) and to develop novel, “personalized” therapies for these disorders. Formed by James Bennett, Jr., M.D., Ph.D., a neurologist physician-scientist with 32 years of biomedical research and patient care experience, NTI uses modern, induced pluripotential stem cell (iPSC) technology combined with next-generation RNA sequencing (RNAseq) to discover how each person’s unique genetic makeup produces molecular “fingerprints” in response to disease and novel experimental therapies. NTI’s goal is to leverage iPSC and RNAseq technologies to predict who will respond better to which drugs and reduce the risk of drug trial failures that currently plague experimental therapeutics of AD, PD and ALS.

There are two major organizing principles behind NTI. First is that these brain conditions are heterogeneous, meaning that like breast cancer, there are multiple molecular origins that vary from person-to-person but produce similar clinical symptoms. Second is the increasing dominance of systems biology as a paradigm for understanding complex diseases. We now recognize that nerve cells are best viewed as interactions among multiple cell biological systems rather than as collections of single genes.

Therapies need to be developed that recognize heterogeneity and systems interactions. Similar to treatments of cancer and HIV, it is likely that multiple drugs in a “cocktail” will be needed for each afflicted person, and the components of that “cocktail” will need to be personalized for the specific molecular deficits present.

Like all non-profit ventures, NTI is supported exclusively by donations. We have no product to sell, do not generate any profits and make all our findings available to our scientific colleagues and the public. We seek your help in solving the problems of these complex brain diseases, so that we and later generations can be free of the substantial personal suffering and financial burdens of these conditions.